Personalized vaccine for early-stage, treatment-free CLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests a personalized cancer vaccine made from each patient’s CLL (“neoantigens”) plus a medicine called poly-ICLC to help the immune system learn to recognize the cancer. It is designed for people who have CLL but are currently not needing treatment, to see if it’s safe and may help keep the disease under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic lymphocytic leukemia (CLL) and meet the study’s criteria for “unmutated” IGHV (less than 2% mutated vs normal).
- You have not received any CLL treatment yet (no prior chemotherapy, targeted CLL drugs, immunotherapy, radiation, or hormone therapy) and your care team expects you likely won’t need treatment in the next 6 months.
- Your CLL is measurable on blood tests (for example, your absolute lymphocyte count is above 10,000, or your white blood cell count is at least 20,000).
- Your blood counts show CLL over time: you must have at least two additional absolute lymphocyte count (ALC) tests at least 2 weeks apart, and at least 2 months before the test used for registration.
- Your health must be strong enough for study treatment (for example: adequate bone marrow and organ function; and good performance status).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
This trial tests a new mRNA vaccine designed to help your immune system fight B-cell lymphoma when standard treatments have stopped working or the cancer has returned. The vaccine is given early in testing to see if it is safe and how well it works, while researchers also check how your body responds.
This trial tests a personalized vaccine made from unique markers on your tumor cells (called neoantigens). The goal is to help your immune system fight the cancer more effectively. It is for people with advanced solid tumors who have not had gene therapy and are otherwise relatively healthy.
This trial offers access to a personalized vaccine made from your tumor's unique markers (neoantigens). The goal is to train your immune system to fight your cancer. You may qualify if standard treatments have not worked or are not an option, and your doctor believes your 5-year survival chance is under 50%.
Hear when a new Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.